Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

Ahmad B. Hamad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8478-2182; OpenAlex author ID A5063793987. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 5 papers

Papers 13

  1. From street address to survival: Neighborhood socioeconomic status and pancreatic cancer outcomes. First author DOI 10.1016/j.surg.2021.10.027↗
  2. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Co-author DOI 10.1016/j.surg.2021.12.029↗
  3. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations. Co-author DOI 10.1016/j.surg.2022.04.018↗
  4. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002083↗
  5. Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10868-4↗
  6. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-021-04984-5↗
  7. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. Co-author DOI 10.3748/wjg.v27.i27.4383↗
  8. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-08156-3↗
  9. Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08249-4↗
  10. Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.hpb.2018.10.012↗
  11. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. Co-author DOI 10.1245/s10434-018-07148-z↗
  12. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Co-author DOI 10.1245/s10434-018-6521-7↗
  13. Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival. Co-author DOI 10.1245/s10434-017-5975-3↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Allan Tsung · 6 shared papers, 2021–2022 · strength 0.94
  2. Jordan M. Cloyd · 4 shared papers, 2021–2022 · strength 0.60
  3. Aslam M. Ejaz · 4 shared papers, 2021–2022 · strength 0.60
  4. Melissa Ellen Hogg · 6 shared papers, 2017–2020 · strength 0.59
  5. Amer H. Zureikat · 6 shared papers, 2017–2020 · strength 0.59
  6. Herbert J. Zeh · 6 shared papers, 2017–2020 · strength 0.59
  7. Mariam F. Eskander · 3 shared papers, 2022 · strength 0.50
  8. Timothy Michael Pawlik · 3 shared papers, 2021–2022 · strength 0.43
  9. Amr I. Al Abbas · 4 shared papers, 2018–2020 · strength 0.42
  10. Jae Pil Jung · 3 shared papers, 2019–2020 · strength 0.34
  11. Caroline J. Rieser · 3 shared papers, 2018–2020 · strength 0.30
  12. Brian A. Boone · 2 shared papers, 2019 · strength 0.20
  13. Zachary J. Brown · 1 shared paper, 2021 · strength 0.17
  14. Mary E. Dillhoff · 1 shared paper, 2021 · strength 0.17
  15. Eliza Wright Beal · 1 shared paper, 2022 · strength 0.16
  16. Heena P. Santry · 1 shared paper, 2022 · strength 0.16
  17. Nathan Bahary · 2 shared papers, 2017–2018 · strength 0.16
  18. Laith I. Abushahin · 1 shared paper, 2022 · strength 0.15
  19. Bradley Norman Reames · 1 shared paper, 2021 · strength 0.12
  20. Matthew John DePuccio · 1 shared paper, 2021 · strength 0.12
  21. Matthew D. Neal · 1 shared paper, 2019 · strength 0.10
  22. Irene Epelboym · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.